Antihypertensive effects of sulforaphane
| dc.contributor.advisor | Juurlink, Bernhard | en_US |
| dc.contributor.advisor | Wu, L. | en_US |
| dc.contributor.committeeMember | Richardson, J. Steven | en_US |
| dc.contributor.committeeMember | Wang, Hui Di | en_US |
| dc.contributor.committeeMember | Kulyk, W. | en_US |
| dc.contributor.committeeMember | Desai, K. | en_US |
| dc.contributor.committeeMember | Lee, P. | en_US |
| dc.creator | Banigesh, Ali | en_US |
| dc.date.accessioned | 2011-03-29T14:42:32Z | en_US |
| dc.date.accessioned | 2013-01-04T04:27:31Z | |
| dc.date.available | 2012-04-06T08:00:00Z | en_US |
| dc.date.available | 2013-01-04T04:27:31Z | |
| dc.date.created | 2011-03 | en_US |
| dc.date.issued | 2011-03 | en_US |
| dc.date.submitted | March 2011 | en_US |
| dc.description.abstract | Persistent hypertension is associated with a greater incidence of organ damage and conditions such as stroke, heart failure and end–stage kidney disease, which results in increased cardiovascular (CV) morbidity and mortality. Among the patients receiving antihypertensive treatment, the level of adequate blood pressure (BP) control ( | en_US |
| dc.identifier.uri | http://hdl.handle.net/10388/etd-03292011-144232 | en_US |
| dc.language.iso | en_US | en_US |
| dc.subject | SHRsp | en_US |
| dc.subject | sulforaphane | en_US |
| dc.subject | hypertension | en_US |
| dc.subject | phase2 protein inducer | en_US |
| dc.title | Antihypertensive effects of sulforaphane | en_US |
| dc.type.genre | Thesis | en_US |
| dc.type.material | text | en_US |
| thesis.degree.department | Pharmacology | en_US |
| thesis.degree.discipline | Pharmacology | en_US |
| thesis.degree.grantor | University of Saskatchewan | en_US |
| thesis.degree.level | Doctoral | en_US |
| thesis.degree.name | Doctor of Philosophy (Ph.D.) | en_US |